PDF(Pubmed)
Abstract：
UNASSIGNED: Diabetes increases preventative sickness and costs healthcare and productivity. Type 2 diabetes and macrovascular disease consequences cause most diabetes-related costs. Type 2 diabetes greatly costs healthcare institutions, reducing economic productivity and efficiency. This cost of illness (COI) analysis examines the direct and indirect costs of treating and managing type 1 and type 2 diabetes mellitus.
UNASSIGNED: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Cochrane, PubMed, Embase, CINAHL, Scopus, Medline Plus, and CENTRAL were searched for relevant articles on type 1 and type 2 diabetes illness costs. The inquiry returned 873 2011-2023 academic articles. The study included 42 papers after an abstract evaluation of 547 papers.
UNASSIGNED: Most articles originated in Asia and Europe, primarily on type 2 diabetes. The annual cost per patient ranged from USD87 to USD9,581. Prevalence-based cost estimates ranged from less than USD470 to more than USD3475, whereas annual pharmaceutical prices ranged from USD40 to more than USD450, with insulin exhibiting the greatest disparity. Care for complications was generally costly, although costs varied significantly by country and problem type.
UNASSIGNED: This study revealed substantial heterogeneity in diabetes treatment costs; some could be reduced by improving data collection, analysis, and reporting procedures. Diabetes is an expensive disease to treat in low- and middle-income countries, and attaining Universal Health Coverage should be a priority for the global health community.
UNASSIGNED: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Cochrane, PubMed, Embase, CINAHL, Scopus, Medline Plus, and CENTRAL were searched for relevant articles on type 1 and type 2 diabetes illness costs. The inquiry returned 873 2011-2023 academic articles. The study included 42 papers after an abstract evaluation of 547 papers.
UNASSIGNED: Most articles originated in Asia and Europe, primarily on type 2 diabetes. The annual cost per patient ranged from USD87 to USD9,581. Prevalence-based cost estimates ranged from less than USD470 to more than USD3475, whereas annual pharmaceutical prices ranged from USD40 to more than USD450, with insulin exhibiting the greatest disparity. Care for complications was generally costly, although costs varied significantly by country and problem type.
UNASSIGNED: This study revealed substantial heterogeneity in diabetes treatment costs; some could be reduced by improving data collection, analysis, and reporting procedures. Diabetes is an expensive disease to treat in low- and middle-income countries, and attaining Universal Health Coverage should be a priority for the global health community.
摘要：
糖尿病会增加预防性疾病，并导致医疗保健和生产力下降。2型糖尿病和大血管疾病的后果导致大多数与糖尿病相关的费用。2型糖尿病使医疗机构付出了巨大的代价，降低经济生产率和效率。这种疾病成本（COI）分析检查了治疗和管理1型和2型糖尿病的直接和间接成本。
■根据系统评价和荟萃分析指南的首选报告项目，科克伦,PubMed,Embase,CINAHL,Scopus,MedlinePlus,和CENTRAL检索了有关1型和2型糖尿病疾病费用的相关文章。调查返回了873篇2011-2023年的学术文章。在对547篇论文进行摘要评估后，该研究包括42篇论文。
■大多数文章起源于亚洲和欧洲，主要是2型糖尿病。每位患者的年度费用从87美元到9,581美元不等。基于患病率的成本估计范围从低于470美元到超过3475美元，而年度药品价格范围从40美元到超过450美元，胰岛素表现出最大的差距。并发症的护理通常成本很高，尽管成本因国家和问题类型而异。
■这项研究揭示了糖尿病治疗成本的巨大异质性；一些可以通过改进数据收集来减少，分析,和报告程序。在低收入和中等收入国家，糖尿病是一种昂贵的疾病，实现全民健康覆盖应该是全球卫生界的优先事项。
■根据系统评价和荟萃分析指南的首选报告项目，科克伦,PubMed,Embase,CINAHL,Scopus,MedlinePlus,和CENTRAL检索了有关1型和2型糖尿病疾病费用的相关文章。调查返回了873篇2011-2023年的学术文章。在对547篇论文进行摘要评估后，该研究包括42篇论文。
■大多数文章起源于亚洲和欧洲，主要是2型糖尿病。每位患者的年度费用从87美元到9,581美元不等。基于患病率的成本估计范围从低于470美元到超过3475美元，而年度药品价格范围从40美元到超过450美元，胰岛素表现出最大的差距。并发症的护理通常成本很高，尽管成本因国家和问题类型而异。
■这项研究揭示了糖尿病治疗成本的巨大异质性；一些可以通过改进数据收集来减少，分析,和报告程序。在低收入和中等收入国家，糖尿病是一种昂贵的疾病，实现全民健康覆盖应该是全球卫生界的优先事项。
